Lineage Cell Therapeutics Inc.
Organization details
- Legal name
- Lineage Cell Therapeutics Inc.
- Former names
- Biotime Inc
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- California
- Headquarters city
- Carlsbad
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- LCTX
- Primary stock exchange
- NYSE American
Identifiers
- SEC CIK
- 0000876343
- EIN
- 94-3127919
Board of directors
-
Alfred D. Kingsley · Director · ChairmanSince 2023
-
Angus C. Russell · DirectorSince 2023
-
Anula Jayasuriya · DirectorSince 2023
-
Brian M. Culley · Director · President and CEOSince 2023
-
Deborah J. Andrews · DirectorSince 2023
-
Dipti Amin · DirectorSince 2023
-
Don M. Bailey · DirectorSince 2023
-
Michael H. Mulroy · DirectorSince 2023
-
Neal C. Bradsher · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 9, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
98.2%
-
98.6%
-
98.7%
-
98.7%
-
98.8%
-
98.8%
-
98.9%
Board connections
4 of this board's directors also sit on 4 other boards. 4 are in the same sector.
-
Insight Molecular Diagnostics Inc. Same sectorvia Alfred D. Kingsley
-
Jaguar Health Inc. Same sectorvia Anula Jayasuriya
-
STAAR Surgical Company Same sectorvia Neal C. Bradsher
-
Structure Therapeutics Inc. Same sectorvia Angus C. Russell
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $24,450
- 1 purchase by 1 insider
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 12, 2026 | Brian M. Culley Director, Officer (President and CEO) | Open-market purchase | +15,000 | $1.63 | $24,450 |
| Feb 11, 2026 | Brian M. Culley Director, Officer (President and CEO) | Option exercise | +31,250 | — | — |
| Feb 11, 2026 | Samuel George A. III Officer (General Counsel and Secretary) | Option exercise | +6,075 | — | — |
| Feb 11, 2026 | Brian M. Culley Director, Officer (President and CEO) | Shares withheld for tax | −12,869 | $1.80 | $23,164 |
| Feb 11, 2026 | Samuel George A. III Officer (General Counsel and Secretary) | Shares withheld for tax | −2,502 | $1.80 | $4,504 |
| Dec 19, 2025 | Brian M. Culley Director, Officer (President and CEO) | Grant or award | +8,925 | — | — |
| Dec 19, 2025 | Samuel George A. III Officer (General Counsel and Secretary) | Grant or award | +1,735 | — | — |
| Dec 19, 2025 | Brian M. Culley Director, Officer (President and CEO) | Shares withheld for tax | −334 | $1.68 | $561 |
| Dec 19, 2025 | Samuel George A. III Officer (General Counsel and Secretary) | Shares withheld for tax | −65 | $1.68 | $109 |
| Feb 11, 2025 | Samuel George A. III Officer (General Counsel) | Option exercise | +6,076 | — | — |
| Feb 11, 2025 | Brian M. Culley Director, Officer (President and CEO) | Option exercise | +31,249 | — | — |
| Feb 11, 2025 | Samuel George A. III Officer (General Counsel) | Shares withheld for tax | −2,440 | $0.65 | $1,586 |
| Feb 11, 2025 | Brian M. Culley Director, Officer (President and CEO) | Shares withheld for tax | −12,547 | $0.65 | $8,156 |
| Jan 27, 2025 | Neal C. Bradsher Director, 10% owner | Open-market purchase | +7,894,737 | $0.76 | $6,000,000 |
| Jan 27, 2025 | Neal C. Bradsher Director, 10% owner | Open-market purchase | +0 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Lineage Cell Therapeutics Inc.
Who is the CEO of Lineage Cell Therapeutics Inc.?
Brian M. Culley is Lineage Cell Therapeutics Inc.'s President and CEO.
How many directors are on Lineage Cell Therapeutics Inc.'s board?
Lineage Cell Therapeutics Inc.'s board has 9 directors: Alfred D. Kingsley, Angus C. Russell, Anula Jayasuriya, Brian M. Culley, Deborah J. Andrews, Dipti Amin, Don M. Bailey, Michael H. Mulroy and Neal C. Bradsher.
Are Lineage Cell Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Lineage Cell Therapeutics Inc. insiders bought $24,450 of shares in 1 purchase and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="lineage-cell-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.